知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.015 秒)

    Process for the preparation of compositions of AT1 receptor antagonist and Angiotensin—(1-7)
    5.
    发明授权
    Process for the preparation of compositions of AT1 receptor antagonist and Angiotensin—(1-7) 失效
    制备AT1受体拮抗剂和血管紧张素（1-7）组合物的方法

    公开(公告)号：US08653031B2

    公开(公告)日：2014-02-18

    申请号：US12513107

    申请日：2006-10-30

    申请人： Rubén Dario Sinisterra Millán ,  Cynthia Fernades Ferreira Santos ,  Robson Augusto Souza Dos Santos ,  Ivana Silva Lula ,  Frederico Barros De Sousa ,  Pedro Pires Goulart Guimaraes ,  Angelo Márcio Leite Denadai

    发明人： Rubén Dario Sinisterra Millán ,  Cynthia Fernades Ferreira Santos ,  Robson Augusto Souza Dos Santos ,  Ivana Silva Lula ,  Frederico Barros De Sousa ,  Pedro Pires Goulart Guimaraes ,  Angelo Márcio Leite Denadai

    IPC分类号： A61K38/00 ,  A61K38/08 ,  A61K38/04 ,  C07K5/00

    CPC分类号： C07K7/14 ,  A61K31/4178 ,  A61K38/085 ,  A61K47/6951 ,  B82Y5/00 ,  A61K2300/00

    摘要： We describe preparation of compounds of an AT1 receptor antagonist(s) and Angiotensin (1-7), for example, Angiotensin-(1-7) losartanate and analogues thereof, and/or mixtures of these systems, pharmaceutical compositions thereof and use of their derivative products. Cyclodextrins and derivatives thereof may be used for the micro-encapsulation of compounds, for example, Angiotensin (1-7) losartanate, liposomes and biodegradable polymers and/or mixtures of these systems and/or derivative products for the obtainment of nano- or microparticles as controlled or sustained release devices of Ang-(1-7) losartanate and analogues and/or mixtures thereof. The compounds may be used as agents for treating or preventing hypertension, cardiovascular diseases, heart hypertrophy, heart failure, coronary diseases, such as angina pectoris, endothelial disorder or endothelial lesions, as a consequence, for example, of atherosclerosis processes or in association with diabetes mellitus. They may also be used in the study and therapy of cardiovascular, renal, reproductive, dermatological, neoplastic, blood and cerebral diseases, and when formulated in controlled release systems, encapsulated or not in cyclodextrins, for use in stent, with a view to modulate the growth of the neointima after catheterization procedures.

    摘要翻译： 我们描述了AT1受体拮抗剂和血管紧张素（1-7）的化合物的制备，例如血管紧张素 - （1-7）氯沙钠及其类似物，和/或这些系统的混合物，其药物组合物和 他们的衍生产品。 环糊精及其衍生物可用于化合物的微胶囊化，例如，血浆紧张素（1-7）氯沙钠，脂质体和可生物降解的聚合物和/或这些系统的混合物和/或用于获得纳米颗粒或微粒的衍生产物 作为Ang-（1-7）氯沙坦酸盐及其类似物和/或其混合物的受控或持续释放装置。 该化合物可用作治疗或预防高血压，心血管疾病，心脏肥大，心力衰竭，冠状动脉疾病如心绞痛，内皮细胞病变或内皮损伤的药物，因此，例如动脉粥样硬化过程或与 糖尿病 它们还可用于心血管，肾脏，生殖，皮肤病学，肿瘤学，血液和脑疾病的研究和治疗，并且当配制在控释系统中时，封装或不包封在环糊精中，用于支架，以调节 导管插入术后新生内膜的生长。